GM2 gangliosidoses (Sandhoff and GM2 activator deficiency)
Log in to starLast updated 3mo ago
A 6-month-old of non-Ashkenazi background has progressive loss of motor milestones, exaggerated startle to sound, hypotonia, and hepatosplenomegaly. Fundoscopy shows a cherry-red macular spot. Hexosaminidase A activity is reduced; total hexosaminidase (A + B) is also reduced, distinguishing this from Tay-Sachs.
All AR. β-Hexosaminidase is a heterodimer; lysosomal hydrolysis of GM2 ganglioside requires the A isoenzyme (αβ) plus the GM2 activator protein as a substrate-presenting cofactor. Defects in any of three components produce a clinically similar lysosomal storage phenotype:
| Disorder | Gene | Defective protein | Hex A activity | Hex B activity |
|---|---|---|---|---|
| Tay-Sachs disease (see tay-sachs-disease) | HEXA | α-subunit | ↓↓ | Normal |
| Sandhoff disease | HEXB | β-subunit (shared by Hex A and Hex B) | ↓↓ | ↓↓ |
| GM2 activator deficiency (AB variant) | GM2A | GM2 activator protein | Normal in vitro | Normal in vitro |
Distinguishing biochemistry, the key teaching point:
- Tay-Sachs: ↓ Hex A, normal total Hex (A + B) → only one of the two isoenzymes lost
- Sandhoff: ↓ Hex A and ↓ Hex B → loss of the shared β-subunit kills both isoenzymes
- GM2 activator (AB): Hex A and Hex B activities are normal in standard assays because the substrate (synthetic 4-MUG) doesn't require the activator, but lysosomal GM2 cannot be hydrolyzed in vivo. Diagnosis is by GM2A sequencing or by enzyme assay using the natural GM2 substrate
Sandhoff disease is panethnic and lacks the strong Ashkenazi Jewish founder effect of Tay-Sachs (though some Ashkenazi-enriched HEXB variants exist). GM2 activator deficiency is exceedingly rare.
The same enzyme deficiency can produce infantile, juvenile, or adult-onset disease, correlating with residual enzyme activity:
- Infantile (most common): onset 3-6 months; rapid neurodegeneration; death by 2-4 years
- Juvenile: onset 2-10 years; ataxia, dysarthria, dementia; death in 2nd decade
- Adult-onset: progressive lower-motor-neuron disease, cerebellar ataxia, psychiatric features (psychosis); slower course
- Onset in early infancy (classical form)
- Loss of acquired motor milestones, hypotonia → eventual decerebrate posturing
- Exaggerated startle response to sound (acoustic myoclonus): a classic clinical finding
- Cherry-red macular spot (also seen in Tay-Sachs, Niemann-Pick A, sialidosis, Farber)
- Macrocephaly (storage)
- Seizures
- Sandhoff additionally:
- Hepatosplenomegaly
- Foam cells in bone marrow
- Cardiomegaly, mild dysostosis multiplex
- These visceral features are absent in Tay-Sachs (Hex B activity preserved → glycolipid catabolism only blocked for GM2-specific α-subunit substrates)
- Enzyme assay in serum/leukocytes (Hex A and Hex B); distinguishes Tay-Sachs (low A, normal B) from Sandhoff (both low)
- Carrier-screening caveat: pseudodeficiency alleles in HEXA can produce false-positive carrier results; molecular confirmation is required
- GM2 activator deficiency: suspected when Hex A/B are normal but the clinical picture fits; confirm by GM2A sequencing
- Universal: pursue molecular testing of the relevant gene to confirm and characterize variants
- Ashkenazi Jewish carrier panels include HEXA (Tay-Sachs) and increasingly HEXB (Sandhoff)
- Pan-ethnic expanded carrier screening covers all three
- Enzyme-based carrier screening for HEXA remains gold standard in Ashkenazi populations because of pseudodeficiency variants
- Supportive only; no disease-modifying therapy currently approved
- Seizure management, nutritional support, respiratory care
- Substrate reduction therapy (miglustat) and gene therapy are under investigation
- Genetic counseling and reproductive options (PGT-M, prenatal diagnosis, donor gametes) for at-risk couples
"Sandhoff has Splenomegaly": Sandhoff has visceral storage (hepatosplenomegaly, foam cells); Tay-Sachs does not, because Sandhoff loses the β-subunit shared by Hex A and Hex B → broader substrate accumulation.